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RNA profiling in biofluids holds promise as both diagnostic and prognostic markers. High expression levels of 
distinctive cell free circulating miRNAs in serum, plasma and cerebral spinal fluid (CSF), have been utilized as 
classifiers to detect and characterize disorders of the central nervous system (CNS). We formulated the 
quantitative theory showing how the results of surprisal analysis enable a reliable inference if tumor cells are 
present in the sample from a single measurement. Subsequently, we develop a molecular beacon-based 
microfluidic chip that enables for fluorescence detection of miRNAs without amplification in low volumes of 
human CSF. Using surprisal analysis, we identified a miRNA classifier that enables high fidelity detection and 
characterization of human brain tumors. We anticipate that this micro-fluidic platform will provide a critical 
translational tool with point of care potential for CNS disorders. 
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Introduction 
MicroRNAs (miRNAs) are increasingly utilized as 
biomarkers for diagnostic and prognostic purposes. By 
binding to messenger RNAs (mRNAs) miRNAs guide the 
RNA-induced silencing complex (RISC) that 
post-transcriptionally represses the expression of 
protein-coding genes. MiRNAs are estimated to control 
about one third of all gene expression [1] and they have been 
shown to play crucial regulatory roles in several cellular 
processes, including proliferation, metabolism, development, 
and apoptosis [2, 3]. Given miRNAs extensive regulatory 
function within the cell, the aberrant expression of miRNAs 
has been studied in several human diseases, such as diabetes, 
arthritis, kidney disease, neurodegenerative disorders and 
cancer [4, 5]. Furthermore, cell free circulating miRNAs stably 
packaged in microvesicles can be detected in human serum, 
urine, plasma and cerebral spinal fluid [6]. In terms of their 
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binding, miRNAs are short, about 22 bases in length, single 
stranded RNA molecules. The molecular beacons (MBs) that 
are used for identifying the miRNAs have a loop of 15-30 
nucleotides that bind to the target sequence. 
In recent studies, it has been demonstrated that expression 
levels of distinctive miRNAs are detectable in patient 
biofluids and can be correlated with different types of 
disorders of the central nervous system (CNS) and to disease 
prognosis [7, 8]. Cerebral spinal fluid (CSF), a clear fluid that 
cushions and delivers nutrients to the CNS and is in direct 
contact with the brain and spine, is a more effective mode of 
understanding symptoms and disorders of the CNS. We 
developed a micro-fluidic technology that employs molecular 
beacon sensing to detect and monitor miRNAs without 
amplification in patients’ CSF, sustaining a linear dynamic 
range of 0.2 to 5 fmol. Utilizing this technology, we were 
able to identify a miRNA classifier unique to primary brain 
tumors, and with high fidelity distinguish patient samples 
using low volumes of CSF. Furthermore, we were able to 
characterize the molecular subtypes of these tumors, as 
defined by the Tumor Cancer Genome Atlas [9], using 
miRNAs present in patient CSF.  
The microRNA classifier was identified by surprisal 
analysis of global microRNA expression levels in tumor and 
control of patients’ tissue samples, as previously described [10,
11]. Shown in Figure 1 are results of surprisal analysis for 
three groups of 20 patients, 10 control and 10 tumor samples. 
Altogether we analyzed 101 samples. We identified a 
tumor-specific miRNA classifier capable of distinguishing 
tumor and non-tumor samples (Table 1). Furthermore, we 
validated this miRNA classifier in an independent cohort of 
patient tumor samples (Supplemental Table 1). Patients 
were selected as described in the Supplementary Materials 
(Materials and Methods). An important component of our 
work is showing quantitatively how we use surprisal 
analysis for a reliable reading by our chip. The theory is 
described in detail in a section of the Supplementary 
Materials. The essential point is that surprisal analysis [10, 11] 
enables us to quantitatively express the probability to 
detect the i’th miRNA in a tumor and non-tumor sample as 
The expressions for the probabilities contain 
parameters that we determine by a fit to the input patient data. 
The large number of patients sampled and the large number, 
534, of miRNAS that were detected is statistically sufficient 
to determine all these parameters. Among all the parameters, 
only the multiplier lambda1 differs for tumor and non-tumotr 
samples, see figure 1. As seen in figure 1 the sign of 1 is 
opposite for the tumor and nontumor samples. The value of 
lambda0 is the same for all patients and all miRNAs. The G’s 
depend on the miRNA but not on the categories. Those 
miRNAs for which Gi1 is particularly high or particularly low 
are listed in table 1. These are the miRNAs that are 
particularly useful as markers because it is for these miRNAs 
that their expression value is as different as it can be. This is 
because the value of Gi1 is the same for either type of sample 
but their value of 1 is opposite. Quantitavely, equation (1) 
implies that the ratio of the expression values of the same i’th 
miRNA differ exponentially
P(i | tumor) P(i | non tumor) = exp - l1(tumor)- l1(non tumor)[ ]Gi1( ).
Using molecular beacons (MBs) targeting the miRNAs in the 
classifier we designed a high-sensitivity and high-affinity 
micro-fluidic chip. Briefly, MBs are fluorescent-labeled 
oligonucleotide chain, typically composed of 25-35 
nucleotides. MBs have three distinct structural components. 
The, generally constructed by 15-30 nucleotides, specifically 
bind the target miRNAs. The stem portion consists of 5-8 
base pairs that reversibly dissociates during binding to the 
P(i | tumor) = exp -l0Gi0 - l1(tumor)Gi1( )
P(i | non tumor) = exp -l0Gi0 - l1(non tumor)Gi1( )
Figure 1. miRNA Analysis of Patient Samples. MiRNA 
analysis of 101 patient tumor samples and non-tumor samples 
reveal a subset of miRNAs unique to the tumor, and capable of 
distinguishing non-tumor and tumor samples, see 
Supplementary Theory 1 for details.  Shown as an example 
are results of surprisal analysis for three groups of 20 patients, 
10 control and 10 tumor samples. The analysis identifies those 
miRNAs that are significantly down-regulated, meaning a 
negative value of the multiplier, l1(n) , see equation (1) 
, in
the non tumor samples (left side). The same miRNAs are 
significantly up-regulated in the tumor samples (right side). 
l1(n) is the multiplier for the constraint that distinguishes 
between tumor and non-tumor samples where n is the index 
of the patient. See [10, 11, 14] for more details about surprisal 
analysis. 
(1)
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target miRNAs. The thermodynamic equilibrium relations 
between the stem portion and double-stranded structure of 
loop portion increases the specificity of MBs compared to 
conventional linear probes. Finally, in the absence of the 
target miRNA, a fluorescence resonance energy transfer 
(FRET) procrss is enabled and observed. Upon target 
miRNA binding, the MBs can no longer undergo FRET due 
to the increased FÖrster radius and as a result an increase in 
fluorescence intensity is observed [12, 13]. These MBs will 
assist in distinguishing the targeted miRNA from unintended 
potential targets; the stem-loop structure destabilizes 
hybridization to larger non-target RNAs. MBs were designed 
to detect miRNAs in the miRNA classifier. To determine the 
number of miRNAs in the classifier necessary to distinguish 
patient samples, we apply a unique theoretical development 
to determine with high probability whether a patient sample 
contains tumor cells. This method of inference is described in 
detail in Supplementary Theory 1. In particular it is shown 
why and how our method of characterization of the 
expression levels, known as surprisal analysis [10, 11], is 
especially suited to identifying those miRNAs that are most 
relevant to distinguish healthy and diseased patients. 
Figure 2. A Microfluidic Chip for miRNA sensing in CSF. A. The micro-chamber array consists of 
2 layers: (i) a poly-D-lysine coated borosilicate glass chips substrate and (ii) a Polydimethylsiloxane 
(PDMS) channel layer (3X8 array of cutouts defines 24 micro-chambers), each for sample loading 
and unloading. MBs were printed onto chips and were excited at 495 nm and emission was 
monitored at 670 nm. B. Analysis of CSF samples from 22 tumor patients were also conducted 
following extraction of RNA using GFF filtration of CSF. Fluorescence emission was scanned from 
triple replicates and averaged across MBs. A loss of FRET behavior (increase in fluorescence 
activity) was detected consistently across MBs from micro-chambers loaded with CSF samples from 
patients with tumors. FRET loss was calculated as fluorescence units observed following CSF 
administration from baseline fluorescence and plotted as percent FRET loss over control (non-tumor 
patient biopsy). All CSF samples from tumor patients exhibited 2 to 3 fold increase in FRET loss. 
Error Bars=standard deviation of triple replicates.  
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To determine the specificity of our MBs, synthetic human 
miRNAs with high sequence homology to the miRNAs in 
our classifier were labeled and cross hybridization was 
observed. As expected, a less than 2% cross-hybridization 
was observed for miRNAs differing by more than one 
nucleotide (data not shown).  
Each MB was coupled to FRET fluorophores, Cy3 and 
Cy5. MBs were then spotted onto epoxide substrate coated 
borosilicate glass chips, to enable MB coupling to glass 
surface (L 75 X W 2 m, 1 mm thick) substrate, using a Sprint 
Inkjet Microarray (ArrayJet). MBs emission was monitored 
(Figure 2). The miRNA classifier consisted of miRNAs with 
expected increased expression in patient tumor samples and 
not in control samples. Since miRNA levels can span 
between two to four orders of magnitude, we also determined 
the linear dynamic range of our array. Briefly, varying 
mixtures of synthetic miRNAs were tested and as expected 
the fluorescence FRET signals were proportional to the input 
miRNA concentration over the entire range examined, 
providing a detection limit of 0.5 fmol and a linear dynamic 
range of nearly two orders of magnitude (data not shown).   
Material and Methods 
miRNA expression data. Level 3 miRNA expression data 
were obtained from The Cancer Genome Atlas (TCGA) data 
portal.  
Surprisal analysis 
Surprisal analysis as previously described [10, 11, 14] was 
utilized to directly compute the probabilities that a particular 
sample is from a diseased or a control patient as shown in 
equations (1). 
Patient sample preparation 
Patient samples were collected by the UCLA School of 
Medicine and the UCLA Department of Pathology for their 
Tissue Repository. None of the authors collected these 
directly from patients. No identifying patient information 
was collected alongside the tissue. All samples were 
deidentified as per HIPAA instructions. The patient samples 
(CSF and biopsy) were provided to this study under a 
protocol approved by the Western Institutional Review 
Board (protocol # 12-001039). In particular, the authors were 
provided with an exempt IRB by the UCLA Human 
Research Review Board specifically for the purpose of this 
study.  The patient samples (WHO Grade IV) were 
collected from patients following informed written consent at 
the David Geffen School of Medicine, University of 
California, Los Angeles. Tissue samples and CSF were for 
patients who did not undergo prior radiation therapy using 
therapeutic subtotal or total resection that were performed 
with image guidance. See [11. 14] for additional details. Patient 
miRNA expression analysis will be deposited in 
GeoAsscession and NCBI.  
RNA extraction 
RNA was isolated using the same procedures and checks 
that we used in earlier work [11.14] on RNA in disease. Further 
quality control and normalization was performed using 
GeneSpring GX 11 (Agilent) following their recommended 
procedures for data handling.  
Molecular beacon design and synthesis 
MBs were designed using miRBase database. FRET 
fluorophores were coupled to the 3’ and 5’, respectively, and 
MBs were subjected to HPLC purification prior to use.  The 
miRNA designs were as previously described. [13] 
Microfluidic chip design and fabrication 
The microfluidic chip consists of 2 layers: (i) an epoxide 
coated borosilicate glass chips (L 75 X W 2 cm, 1 mm thick) 
substrate and (ii) a Polydimethylsiloxane (PDMS) channel 
layer (3X8 array of cutouts defines 24 microchambers, each 
with length 9 mm, width 1mm, and volume 50 uL. Drilled 
inlet and outlet holes (a pair of 1mm-diameter holes for each 
microchamber) were also constructed for sample loading and 
unloading. MBs were printed onto chips using a Sprint Inkjet 
Microarray (ArrayJet).  MBs were excited at 495 nm and 
emission was monitored at 670 nm using and confirmed by 
microscopy.  
Sample handling 
Prior to loading onto the chip, the mirVana miRNA 
isolation kit (Ambion, Austin, TX) was used to isolate RNA. 
GFF filtration was used for CSF samples.  Samples were 
allowed to incubate for 2 hours at 37C. At high temperatures 
the helical order of the MB stem gives way to a random-coil 
configuration. Fluorescence versus temperature profiles of 
the molecular indicate that the molecular beacon is suitable 
for assays that are performed below 55 °C (42`C), because 
below 55 °C the free molecular beacons remain dark, yet the 
probe-target hybrids form spontaneously and are stable. 
Florescence emission was averaged across MBs in the 
signature and compared to the fluorescence emission from 
controls.  
Summary, materials and methods 
Patient samples from 53 tumor and 48 non-tumor brain 
tissue biopsies were homogenized and subjected to RNA 
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extraction preparation, as described in the Supplemental 
Material (Materials and Methods) prior to loading onto the 
PDMS micro-chambers to prevent cross-hybridizing to 
pri-miRNA, pre-miRNA and other small non-coding RNAs 
(Supplemental Figure 1). Non-tumor patient biopsy samples 
were extracted from individuals not matched to the tumors in 
this study.  Patient selection was conducted as described in 
Supplementary Section (Material and Methods). Samples 
were then loaded onto the micro-chambers in triplets. The 
array fluorescence was scanned thrice and the response 
averaged across scans. Fluorescence scans of the MB-based 
array showed classifier-specific FRET behavior from tumor 
biopsy samples with more than two-fold increase in 
fluorescence emission, or loss of FRET, seen only from 
tumor patient samples. Only residual low florescence activity 
from non-tumor biopsy samples was detected, and no 
changes in FRET were observed (Supplemental Figure 1). 
Results 
Recent studies have reported the presence of miRNAs in 
cerebral spinal fluid (CSF) [6]. Subsequently, we determined 
whether we could use the small amounts of RNA that can be 
recovered from the volumes of CSF available clinically 
(300-500uL), usually following lumbar puncture or surgical 
resection, on this microfluidic chip. We isolated RNA from 
CSF samples using glass fiber filters (GFF) prior to loading 
into the micro-fluidic chip.  Approximately 50 µl of CSF 
provided 10 to 15 ng of total RNA. The GFF was placed in 
inlets fabricated prior to patient samples entering 
micro-chambers, (at a flow rate of 50 µl min−1 to separate 
RNA from the CSF patient sample). Residual CSF was 
disposed. GFF-mediated extracted RNA from CSF samples 
was then sent into micro-chambers to monitor for MB 
hybridization and subsequent FRET loss. Fluorescence scans 
of the MBs from 22 individual patient CSF samples, showed 
tumor signature-specific FRET behavior (loss of FRET) from 
tumor CSF samples, similar to the scans of the tumor patient 
biopsy samples, with an increase in fluorescence emission, or 
loss of FRET in MBs and no change in FRET behavior from 
non-tumor patient CSF samples (Figure 2B).  
Recently, an effort lead by the Cancer Genome Atlas 
(TCGA) network identified four molecular subclasses of 
tumor-specific genes capable of possibly characterizing 
sub-phenotypes of astrocytomas: Classical, Proneural, Neural 
and Mesenchymal. Each of these subclasses displayed unique 
gene expression profiles [8]. We anticipated that the miRNA 
classifier we identified provided predictive value for further 
characterization of the heterogynous tumor composition and 
cancer cell population dynamics. The miRNAs that compose 
the classifier have regulatory functions targeting genes 
critical to each of the four molecular subclasses. Specifically, 
miRNAs of our classifier have conserved binding site on the 
3’ UTR of many of the selected genes that are critical for 
sustaining these subclasses of astrocytomas (Supplemental 
Table 2). In the Proneural subclass, PDGFR was up regulated 
in patient tumor biopsy samples. We predict a 
down-regulation of miR-7, a miRNA in our cancer-specific 
classifier, in the Proneural subclass of tumor samples. MiR-7 
has a conserved binding site on the 3’ UTR of the PDGR 
transcript, unveiling possible miRNA and mRNA networks 
that regulate the molecular processes underlying these 
distinct subclasses. Similar networks were identified for both 
the Classical and Neural subtypes (Supplementary Table 2). 
Conversely, genes that are down regulated in a specific 
tumor subclass are correlated with an up-regulation of their 
corresponding miRNAs, which have conserved binding sites 
to their 3’UTR. In the Mesenchymal subtype for example, 
NFI is down regulated and our miRNA classifier shows an 
up-regulation of miR-25 and mir-27a, as expected. Both 
miR-25 and miR-27a have conserved binding sites of on the 
3’UTR of NFI. With additional characterization of the four 
subclasses of these brain cancers, we anticipate that miRNA 
classifiers in the CSF may illuminate tumor composition and 
predict resistance to therapeutics.  
Discussion 
Sensing biofluids from a patient is typically done once or 
at best a few times. Yet it is clearly essential that the 
inference made about the sample being from a tumor or a 
non-tumor is as reliable as possible. To recognize that there 
is an inherent problem consider the far simpler decision as to 
whether a coin is honest or tempered with. A single toss of 
this coin will not provide a reliable answer. If it is important 
to know about the coin, many people will guesstimate that at 
least a dozen tosses are required. There is a similar problem 
for us, namely how can a single measurement by the chip get 
us a reliable inference. For both the chip and the coin we 
need to make one binary decision, tumor/non-tumor in our 
case, based on one measurement. There is however a key 
difference that enables us to make a reliable decision. Unlike 
the case of the single coin toss we have the essential 
advantage that in a single sensing we can read the 
fluorescence from several molecular beacons. To design a 
chip we need to determine how many is several and we need 
to quantify reliable. It is one of the key advantages of our 
approach to the analysis of miRNA expression levels, known 
as surprisal analysis [10, 11, 14], that it is optimally suited to 
deliver the required answers on both issues. The 
mathematical formulation is developed in the supplementary 
materials (Supplementary Theory 1). What we show is that 
using our miRNA classifier we can get a reliable inference, 
98% confidence, using the chip design as described above. 
The key is the opposite change in expression levels of certain 
miRNAs in tumor and non-tumor patients as shown in figure 
1. Moreover, as shown in Table I of the supplementary
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materials, there are miRNAs that similarly have a high 
deviation in different cohorts of patients.  
The mathematical result for the reliability when we 
measure the fluorescence from a single beacon is given by 
equation (7) of Supplementary Theory 1. For a single 
miRNA the difference in expression levels of non-tumor and 
tumor patient samples, while large, is not sufficient to 
generate a reliable inference. One cannot rely on monitoring 
just one miRNA to provide a reliable inference. But by 
reading several beacons we extend the reliability to the value 
given by equation (8) of the SI. The miRNAs most useful for 
increasing the reliability of the sensing are listed in 
Supplementary Table I. It is shown that there are enough 
miRNAs that consistently differ to a high extent in different 
cohorts of patients to insure a reliable inference from a single 
sensing.  
In summary, it is the observation that more than one 
miRNA is consistently very different in the expression level 
in non-tumor and tumor patient samples that enables us to 
design a reliable chip.  
MB-based sensing in biofluids, such as cerebral spinal 
fluid, can provide a point-of care platform for detecting CNS 
associated diseases, monitoring disease progression and 
characterizing diseases of the CNS using a less invasive and 
less high-risk module through analysis of CSF in lieu of 
patient biopsy sample extraction. 
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Supplementary Data 
Supplementary Theory 1 
In this supplement we demonstrate that the results of 
surprisal analysis of real patient data enable us to design a 
chip that reliably determines the probability that a particular 
patient is diseased or is not. The issue is that we only 
perform a single reading of the chip or at best, a few 
replicated. It is therefore necessary to define an ‘event’ that is 
sure to take place with a very high probability so that a single 
experiment will suffice. Technically, the design desideratum 
is that the decision that a patient is diseased is made with as 
high a reliability as is realistically possible. The input to 
knowing the probability that a patient is diseased is the 
reading of the chip for the patient’s biopsy sample. In the 
main text we reported that surprisal analysis provided a clear 
signature that distinguishes between tumor and non tumor 
patients, see Figure 1 of the main text. In detail it means that 
many miRNAs are up regulated in the tumor patients and 
down regulated in the non tumor patients AND that many 
other miRNAs are down regulated in the tumor patients and 
up regulated in the non tumor patients. In other words, for 
tumor patients we generate a list of miRNAs where those at 
the top are most up regulated and those at the bottom are 
most down regulated. Surprisal analysis further shows that 
there is an exactly complementary list for the non tumor 
patients. Keeping the list the same, for non tumor patients the 
miRNAs at the top of the list are most down regulated and 
those at the bottom are most up regulated.   
We show below that the essential observation that we 
derive from surprisal analysis is that the gap between the up- 
and the down-regulated miRNAs is wide enough that with 
reading the level of just a few miRNAs we can already 
provide a reliable reading for the probability that a patient is 
or is not diseased. These few miRNA’s constitute the 
classifier and are listed in Table 1 of the main text. It is 
therefore practical to construct a chip as discussed in the 
main text. In this section we assume that, as discussed in the 
main text, the chip reads the level of several miRNAs. We 
need to show that the number of miRNAs whose level needs 
to be determined is small enough that it can be read by a 
single chip. Fortunately the results for tumor samples are 
such there is much scope for a margin of safety and one can 
readily read more than double the number of miRNAs that is 
strictly necessary. We therefore begin with a list of miRNAs 
whose level in the biopsy sample of the patient has been 
read. This we call the chip data for the patient. Given this 
data we want to compute the probability that the patient is 
diseased. The point is to read enough miRNAs until this 
probability is very high, as near to one as possible or it is 
very low, as near to zero as possible. In the notation of 
probability theory the probability we want to determine is 
written as. We compute the probability of disease given the 
chip read data from Bayes theorem 
In equation (1), is the 
probability that we get the reading that we got given that the 
patient is diseased. The problem is in the denominator of 
equation (1), which requires as an input a probability that we 
do not have. To bypass this problem we write an equation 
completely analogous to (1) but for a non tumor patient: 
Therefore, given the chip data we have that 
We here take the view that a patient is either non tumor or 
tumor so that =
and therefore (3) can be 
rewritten as 
We do not know exactly what is the probability that a 
randomly chosen person is diseased with tumor. From US 
population data the probability is about 3 in 100,000. It does 
not matter if the estimate is somewhat off because the final 
result will not be sensitive to the exact value. We put 
 and therefore we can solve equation (4) for 
the probability of interest 
We will compute the two probabilities that we need, 
 and
 from surprisal analysis 
of data of both non tumor and tumor patients (15). We take 
into consideration that the chip is designed to read a few 
miRNAs that are up regulated. The dominant pattern 
identified by surprisal analysis distinguishes between tumor 
and non tumor patients. Explicitly in a tumor and non tumor 
patients the probability of the i’th miRNA is (15) 
P tumor | chip data of patient( ) =
P tumor | without patient data( )
P chip data of patient | tumor( )
P chip data of patient ( )
P chip data of patient | tumor( )
P non tumor | chip data of patient( ) =
P non tumor | without patient data( )
P chip data of patient | non tumor( )
P chip data of patient( )
P tumor | chip data of patient( )
P non tumor | chip data of patient( )
=
P tumor | without patient data( )
P non tumor | without patient data( )
P chip data of patient | tumor( )
P chip data of patient | non tumor( )
P non tumor | chip data of patient( )
1-P tumor | chip data of patient( )
P tumor | chip data of patient( )
1- P tumor | chip data of patient( )
=
P tumor( )
1- P tumor( )
P chip data of patient | tumor( )
P chip data of patient | non tumor( )
P tumor( )
1- P tumor( )
= 3×10-5










P chip data of patient | non tumor( )
P chip data of patient | tumor( )
=
1
1+ e10.4( ) P chip data of patient | non tumor( )
P chip data of patient | tumor  ( )
P chip data of patient | tumor ( )
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where typically see figure 1 
of the main text. Then 
We sort the miRNAs so that i =1 is the most up regulated. i =2 is the 
next most up regulated, etc. To collect enough evidence we need to 
measure the overexpression of m miRNAs 
This brings us to the result we need for equation (5) 
so that 
We therefore need to include as many miRNAs on the chip 
such that, see equation (9), the number m satisfies 
We need the exponent to be at least 13.4 if we need a 
probability of better than 95%. We need an exponent larger 
than 14.4 if the probability is to be larger than 98% etc. This 
is relatively easy to achieve even with few miRNAs because 
the difference is a rather 
large negative number as shown in Figure 2B of the main 
text. 
Supplemental Table 1. MiRNA analysis reveal consistent miRNA 
classifiers between TCGA and UCLA patient cohorts. Overlap of 
miRNAs between the two cohorts was color-matched to highlight 
the similarity 



















Supplemental Table 2. Characterization of Tumor 
Subclasses. Genes that are up regulated in a specific 
subclass of the tumor, have 3’UTR sites that are 
conserved to miRNAs in the classifier, exhibiting a mRNA 
and miRNA network response. Conversely, genes that are 
down regulated in a subclass (blue*) are correlated with 
an up-regulation of miRNAs that have conserved binding 
sites to their 3’ UTR. 













P(i | tumor) = exp -l0Gi0 - l1(tumor)Gi1( )
P(i | non tumor) = exp -l0Gi0 - l1(non tumor)Gi1( )
P(i | tumor)
P(i | non tumor)
= exp - l(tumor)- l(non tumor)( )Gia( )
P chip data of patient| tumor( )
P chip data of patient| non tumor( )
= exp - l(tumor)- l(non tumor)( ) Giai=1
m
å( )
P tumor | chip data of patient( ) =
1
1+ e10.4( )exp l(tumor)- l(non tumor)( ) Giai=1
m
å( )
- l(tumor)- l(non tumor)( ) Giai=1
m
å( ) >10.4





Supplemental Figure 1. Results of an analysis of 22 tumor 
and 22 control patient biopsy samples. Fluorescence 
emission was scanned and the data averaged across MBs. A 
significant loss of FRET behavior (increase in fluorescence 
activity) was detected from micro-chambers loaded with tumor 
patient biopsy samples. Red=control samples, Blue=tumor 
patient biopsy samples, Error Bars=standard deviation of triple 
replicates.   
